Neuphoria Therapeutics posts Q4 income before income taxes of USD 1.83 million, reversing a loss

Lynx1 Capital Management - on Dec 26, Offered to Acquire Neuphoria Therapeutics' Ip Assets via Cash or Equivalent Stock - SEC Filing

Neuphoria Therapeutics Inc. Held Annual Shareholder Meeting

Leading Proxy Advisory Firm Iss Recommends That Shareholders Vote the White Proxy Card for Both of Neuphoria’s Director Nominees

Press Release: Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees

Neuphoria Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $7 From $21

Neuphoria Therapeutics Inc - Lynx1's New Bid Lower Than Initial $4.75 per Share

Neuphoria Therapeutics Inc - Pauses R&D Expenditures for Bnc210 in Ptsd & Is Evaluating All Possibilities as Part of the Co's Strategic Review

Neuphoria Therapeutics Inc - Received Substantial Competing Indications of Interest

Neuphoria Therapeutics Inc - Urges Stockholders to Vote "for" Both of Neuphoria's Nominees on White Proxy Card

Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium

Lynx1 Capital Management Lp Says on Dec 2, Deliveres Letter to Neuphoria Therapeutics' Board - SEC Filing

Lynx1 Capital Management - Letter to Neuphoria Therapeutics Contains Non-Binding Proposal to Buy Co's Outstanding Shares for $4.75/Share in Cash

Press Release: Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

Neuphoria Therapeutics: Strategic Review Process Is Well Underway

Neuphoria Therapeutics Faces Proxy Battle as Dissident Investor Nominates Rival Directors

Lynx1 Capital Management Lp - Withdraws Previous Non-Binding Proposal to Acquire Neuphoria Therapeutics - SEC Filing

BRIEF-Neuphoria Therapeutics May Offer & Sell Common Stock Of Up To $20 Million From Time To Time - SEC Filing

Neuphoria Therapeutics Inc - May Offer & Sell Common Stock of up to $20 Mln From Time to Time - SEC Filing